Advertisement for orthosearch.org.uk
Results 1 - 12 of 12
Results per page:
Orthopaedic Proceedings
Vol. 84-B, Issue SUPP_III | Pages 236 - 236
1 Nov 2002
Ip W Gogolewski S
Full Access

Background: Healing of segmental diaphyseal bone defects in animals can be enhanced by covering the defects with resorbable polylactide membranes. Based on the results of bone healing in defects 10 mm long in the rabbit radii, it was suggested that the membrane prevents muscle and soft tissue from invading the defect and maintains osteogenic cells and osteogenic substances within the space covered with membrane, thus promoting new bone formation. However, for bone defects larger than a critical size, bone healing did not occur when covered with polylactide membrane. Objectives: To investigate and compare bone regeneration with resorbable polylactide membrane and polylactide sponge in a 20 mm bone defect in rabbit radii. The material used was polylactide (L/DL) 80/20/1. To determine and compare the biomechanical strength of the bone fixation construct with reinforcement by membrane and sponge of such bone defect which were rendered unstable by ulnar osteotomy. Material & method: 20 mm long diaphyseal segmental defects were made in the left radii of adult New Zealand rabbits. Transverse ulnar osteotomies were made at mid-shaft to make the forearm unstable. The rabbits were divided into 4 groups. In group 1, no fixation of the bone were performed and the limbs were immobilized in a plaster for 8 weeks. In group 2, the bone defects were fixed with 1.5 AO miniplate, with 2 screws on each side of the defect. In group 3, the bone defects were fixed similarly and polylactide membranes were used to cover up the bony defect. In group 4, the bone defects were fixed similarly to group 2 and the defects were bridged by sponge of 20 mm long, 3.5 mm in diameter. In group 5, the bone defects were bridged by sponge similar to group 4 and were also covered by polylactide membrane and similar internal fixation were performed. Results: In group 1, there was bone healing bridging the bone ends. However, there was marked shortening of the limbs and all the limbs were deformed. In group 2, there were bone formation at the ends of both proximal bone stumps and distal bone stumps. There was no bone bridging the defect. In group 3,4, there were bone formation across the defect. There was more bone formation in group 4, i.e. the defects were bridged by sponge. Conclusion: Polylactide membrane and sponge promote bone regeneration in 20 mm both defects in the rabbit radii model. There was more bone formation when sponged were employed


Orthopaedic Proceedings
Vol. 92-B, Issue SUPP_II | Pages 314 - 314
1 May 2010
Efstathopoulos N Nikolaou V Tsiolis P Lazarettos I Tsaganos T Koutoukas P Frangia K Korres D Giamarellosbourboulis E
Full Access

Introduction: Biodegradable systems releasing antibiotics are promising candidates for the management of chronic osteomyelitis. Gentamicin and fluoroquinolones are the commonest antibiotics applied with these systems. The effectiveness of a new system from polymerized dilactide (PLA) with incorporated linezolid has been investigated in a rabbit model for treating osteomyelitis by methicillin-resistant Staphylococcus Aureus (MRSA).

Methods: The PLA – Linezolid system was made after thorough stirring 2gr of polymer with 100 mg of linezolid. Experimental osteomyelitis was established in 40 rabbits by a modification of the Norden model. Methicillin-resistant Staphylococcus aureus (MRSA) was applied as the test isolate. After drilling a hole in the upper right femur, the isolate was inoculated along with a thin needle working as a foreign body. After three weeks the needle was removed and cultured and PLA-Linezolid system was implanted in half of the animals. Animals were sacrificed at regular time intervals and tissue around the site of implantation was sent for histologic examination and quantitative cultures.

Results: At 2 – 4 – 6 – 8 – 10 weeks time after removal of the needle results (mean values) were as follows (Controls/PLA-Linezolid): Log10 (cfu/g) at infection site: 2.99/5.68 – 3.44/3.20 – 3.22/2.39 – 1.00/1.27 – 1.00/1.00 respectively and Δlog10 (cfu/g) compared to start: −0.05/−3.23 – 0.23/0.13 – 0.05/0.93 – 1.34/1.09 – 3.31/3.34 respectively. Histology confirmed the previous mentioned results, showing an early decrease following by late recurrence of the infectious reaction at the animals that PLA-Linezolid system was used.

Conclusions: It is concluded that the applied system achieved an early decrease of the tissue bacterial load which was not maintained until late on follow-up. This might be explained by the bacteriostatic mode of action of linezolid.


Bone & Joint Research
Vol. 2, Issue 2 | Pages 26 - 32
1 Feb 2013
Neumann H Schulz AP Gille J Klinger M Jürgens C Reimers N Kienast B

Objectives

Osteochondral injuries, if not treated adequately, often lead to severe osteoarthritis. Possible treatment options include refixation of the fragment or replacement therapies such as Pridie drilling, microfracture or osteochondral grafts, all of which have certain disadvantages. Only refixation of the fragment can produce a smooth and resilient joint surface. The aim of this study was the evaluation of an ultrasound-activated bioresorbable pin for the refixation of osteochondral fragments under physiological conditions.

Methods

In 16 Merino sheep, specific osteochondral fragments of the medial femoral condyle were produced and refixed with one of conventional bioresorbable pins, titanium screws or ultrasound-activated pins. Macro- and microscopic scoring was undertaken after three months.


Orthopaedic Proceedings
Vol. 94-B, Issue SUPP_XLI | Pages 149 - 149
1 Sep 2012
Ahmed M
Full Access

Massive segmental bone defects in long bones remain a considerable clinical challenge and are a source for significant morbidity and prolonged dysfunction for the patient. We demonstrate the successful use of resorbable polylactide membranes as a scaffold for autologous bone graft in the treatment of a 10cm traumatic femoral bone defect. A 28-year-old male was involved in a motorcycle accident vs. tree at 140k/hr. He sustained a Gustillo grade 3b intercondylar fracture of his right femur, and a 10cm piece of his femoral bone found at the scene was brought to Emergency in a sterile container. He was taken to theatre for debridement and ORIF of the intercondylar fracture, with vacuum dressing cover. Day 5 post injury the patient returned to theatre and the LISS plate was revised to correct the rotation and 3cm shortening. The 10cm cortical defect now present was filled with antibiotic cement (Palacos) and delayed primary closure was performed. Day 21 post injury the cement spacer was removed and replaced with two polylactide membrane tubes, one within the medullary canal and the other around the outside of the bone. The “neocortical” space thus produced was grafted with cancellous autograft mixed with bone morphogenic protein (OP1, Stryker). The remainder of the post-operative course was uncomplicated and the patient was discharged home 5 days later. The patient was reviewed at the 6 week and 3 month mark post injury. The femoral defect demonstrated both radiological and clinical union at the 3 month mark and full weight bearing was permitted. His range of motion at that stage was 5 to 95 degrees with no sign of infection. The use of polylactide membranes as a scaffold in the treatment of segmental long bone defects is an excellent and relatively straightforward technique. Forming a space between the 2 tubes controls cancellous graft to the site of the cortical area where it is required and the polylactide membrane then resorbs over years producing CO2 and water. This case demonstrates that the use of polylactide membranes is safe and effective in the management of segmental long bone defects


Orthopaedic Proceedings
Vol. 92-B, Issue SUPP_III | Pages 412 - 412
1 Jul 2010
Getgood A Brooks R Fortier L Rushton N
Full Access

Introduction: Platelet rich plasma (PRP) has been hypothesised to be of potential benefit to articular cartilage tissue engineering, through its release of autologous growth factors. The aim of this study was to ascertain whether the addition of thrombin is required to achieve platelet activation and sustained growth factor release in-vitro, when PRP is applied to a collagen based osteochondral scaffold. Methods: Collagen/glycosaminoglycan scaffolds were fashioned, to which equal combined volumes of test substances were added (n=3): 500μl PRP; 375μl PRP + 125μl autologous thrombin (3:1); 455μl PRP + 45μl bovine thrombin (10:1). One ml of DMEM/F12 medium was added to each scaffold and changed completely at 12/24 hours, and 3/10 days, following which release of TGF-β1, PDGF-AB and bFGF were measured using ELISA. Secondly, equal sized collagen/glycosaminogly-can and polylactide co-glycolide scaffolds were fashioned to which 500μl of PRP were added (n=3). Similar conditions were followed as previously except that only PDGF-AB was assayed. Results: A similar cumulative release profile of all growth factors was found over the 10 day period. Greater growth factor release was seen in the PRP only group at all time points with PDGF-AB in particular reaching statistical significance at all time points (p< 0.006). These findings remained apparent when a correction for volume was made (p< 0.028) suggesting a particular role of the collagen in platelet activation. This was shown in the second experiment, in which a significantly increased cumulative volume of PDGF-AB was released from the collagen/glycosaminoglycan scaffold without thrombin activation (p< 0.04). Discussion: This study shows that collagen is a potent activator of platelets, requiring no further addition to achieve satisfactory growth factor release when applied clinically. These results suggest that if PRP is combined with polylactide co-glycolide scaffolds, it should be activated with thrombin to achieve optimum growth factor release


Orthopaedic Proceedings
Vol. 100-B, Issue SUPP_4 | Pages 20 - 20
1 Apr 2018
Gasik M Haaparanta AM Muhonen V Zühlke A Laine K Bilotsky Y Kellomäki M Kiviranta I
Full Access

Use of scaffolds for articular cartilage repair (ACR) has increased over the last years with many biomaterials options suggested for this purpose. It is known that scaffolds for ACR have to be optimally biodegradable with simultaneous promotion of chondrogenesis, favouring hyaline cartilage formation under rather complex biomechanical and physiological conditions. Whereas improvement of the scaffolds by their conditioning with stem cells or adult chondrocytes can be employed in bioreactors, “ideal” scaffolds should be capable of performing such functions directly after implantation. It was previously considered that scaffold structure and composition would be the best if it mimics the structure of native cartilage. However, in this case no clear reparative stimuli are being imposed on the scaffold area, which would drive chondrocytes activity in a desired way. In this work, we studied new xeno-free, recombinant human type III collagen-laden polylactide (PLA) mesh scaffolds, which have been designed, produced, and biomechanically optimized in vitro and in vivo validated in a porcine and equine model. The scaffolds were additionally assessed for relative performance simulated synovial fluids for both human conditions and veterinary cases. It was experimentally shown that success of the scaffolds in ACR eventually require lower stiffness than surrounding cartilage yet matching the strain compliance, different in static and dynamic conditions. This ensures an optimal combination of load transfer and oscillatory nutrients supply to the cells, which otherwise is difficult to rely on just with a passive diffusion in avascular cartilage conditions. The results encourage further development of such scaffold structures targeted on their best clinical performance rather than trying to imitate the respective original tissue. The authors would like to thank Finnish Agency for Innovation (Tekes) for providing financial support to this project. A.Z. also acknowledges Teknos Foundation (Finland) for the scholarship


Orthopaedic Proceedings
Vol. 95-B, Issue SUPP_12 | Pages 22 - 22
1 Mar 2013
Jordan C Quaye M Madi K Hsu Y Tong J Cossey A
Full Access

The treatment of acute full thickness chondral damage within the knee is a surgical challenge. Frequently used surgical techniques include chondroplasty, micro-fracture and chondrocyte implantation. These procedures give unpredictable functional outcomes and if the formation of neocartilage is achieved it is predominantly composed of type 1 collagen. The TruFit osteochondral plug was designed to provide a scaffold for cell proliferation into full thickness chondral defects. It is a composite polymer composed of polylactide co-glycolide, calcium sulphate and poly-glycolide fibres. It is composed of 2 layers, one with a similar trabecular network to cancellous bone and a superficial layer designed to simulate articular lining. The TruFit bone plug was analysed using micro-computed tomography. Its morphology characteristics, granulometry, mechanical performance and image guided failure were tested as well as numerical modelling to assess the permeability of TruFit. Morphological parameters of the TruFit bone plug compared favourably with those of human tissue. Under load the scaffold exhibited shear bands throughout the composite leading to a failure mechanism similar to cancellous bone. Stress relaxation rates of the scaffolds were greatly decreased under wet conditions, likely due to plasticisation of the scaffold by water. The biomechanical properties of the TruFit bone plugs are a cause for concern. The Scaffolds mechanical performance under load rapidly deteriorates in wet conditions at body temperature (the natural knee environment). This early failure will lead to defects in the articular surface where the plug has been inserted. Clinical data is sparse. This study correlates with work performed by Dockery et al & Spalding et al. These clinical studies have shown that the TruFit implant shows no evidence of bone ingrowth or osteoconductivity. It provides no subchondral support to neocartilage or tissue that was stimulated to form around the defects and surgical sites


Orthopaedic Proceedings
Vol. 86-B, Issue SUPP_III | Pages 343 - 344
1 Mar 2004
Tielinen L Lindahl J Koskinen S Hirvensalo E
Full Access

Aims: Meniscus repair has become the procedure of choice for the treatment of meniscal tears whenever possible. However, problems with healing of the repaired meniscus do exist. We have assessed both clinically and with MRI the outcome of meniscal ruptures treated with bioabsorbable arrows. Methods: 74 consecutive patients with 80 longitudinal vertical meniscal tears were treated using polylactide meniscus arrows (Bionx Implants Ltd, Tampere, Finland) during a three year period. Half of the patients had an old meniscal tear (> 6 weeks). The average length of the follow-up was 25 months (range, 6–56 months). The patients who had not received secondary surgery for failed repair during the follow-up period were examined clinically and with MRI. Results: 56 out of 80 meniscal ruptures (70%) healed clinically. However, in 7 of these asymptomatic patients the MRI showed partial healing. In repairs performed in conjunction with ligament reconstruction the healing rate was higher (82%) than in the isolated tears (62%). The poorest results were seen in the very long vertical tears with luxation of the meniscus (43% healing rate). Conclusions: Bioabsorbable arrows offer a good alternative for the treatment of meniscal ruptures, but special attention should be payed on the reliability of the þxation. In long and unstable tears we suggest combined þxation techniques to be used; arrows for the þxation of the posterior horn and inside-out sutures for the corpus area


Orthopaedic Proceedings
Vol. 93-B, Issue SUPP_III | Pages 307 - 307
1 Jul 2011
Getgood A Brooks R Fortier L Rushton N
Full Access

Introduction: Platelet rich plasma (PRP) has been hypothesised to be of potential benefit to articular cartilage tissue engineering, through its release of autologous growth factors. The aim of this study was to ascertain whether the addition of thrombin is required to achieve platelet activation and sustained growth factor release in-vitro, when PRP is applied to a collagen based osteochondral scaffold. Methods: Collagen/glycosaminoglycan scaffolds were fashioned, to which equal combined volumes of test substances were added (n=3): 500μl PRP; 375μl PRP + 125μl autologous thrombin (3:1); 455μl PRP + 45μl bovine thrombin (10:1). One ml of DMEM/F12 medium was added to each scaffold and changed completely at 12/24 hours, and 3/10 days, following which release of TGF-β1, PDGF-AB and bFGF were measured using ELISA. Secondly, equal sized collagen/glycosaminoglycan and polylactide co-glycolide scaffolds were fashioned to which 500μl of PRP were added (n=3). Similar conditions were followed as previously except that only PDGF-AB was assayed. Results: A similar cumulative release profile of all growth factors was found over the 10 day period. An increase in growth factor release was seen in the PRP only group at all time points with PDGF-AB in particular reaching statistical significance at all time points (p< 0.006). These findings remained apparent when a correction for volume was made (p< 0.028) suggesting a particular role of the collagen in platelet activation. This was shown in the second experiment, in which a significantly increased cumulative volume of PDGF-AB was released from the collagen/glycosaminoglycan scaffold without thrombin activation (p< 0.04). Discussion: This study shows that collagen is a potent activator of platelets, requiring no further addition to achieve satisfactory growth factor release when applied clinically. These results suggest that if PRP is combined with polymer scaffolds, it should be activated with thrombin to achieve optimum growth factor release


Orthopaedic Proceedings
Vol. 93-B, Issue SUPP_I | Pages 70 - 71
1 Jan 2011
Getgood A Brooks R Fortier L Rushton N
Full Access

Introduction: Platelet rich plasma (PRP) has been hypothesised to be of potential benefit to articular cartilage tissue engineering, through its release of autologous growth factors. The aim of this study was to ascertain whether the addition of thrombin is required to achieve platelet activation and sustained growth factor release in-vitro, when PRP is applied to a collagen based osteochondral scaffold. Methods: Collagen/glycosaminoglycan scaffolds were fashioned, to which equal combined volumes of test substances were added (n=3): 500μl PRP; 375μl PRP + 125μl autologous thrombin (3:1); 455μl PRP + 45μl bovine thrombin (10:1). One ml of DMEM/F12 medium was added to each scaffold and changed completely at 12/24 hours, and 3/10 days, following which release of TGF-β1, PDGF-AB and bFGF were measured using ELISA. Secondly, equal sized collagen/glycosaminogly-can and polylactide co-glycolide scaffolds were fashioned to which 500μl of PRP were added (n=3). Similar conditions were followed as previously except that only PDGF-AB was assayed. Results: A similar cumulative release profile of all growth factors was found over the 10 day period. An increase in growth factor release was seen in the PRP only group at all time points with PDGF-AB in particular reaching statistical significance at all time points (p< 0.006). These findings remained apparent when a correction for volume was made (p< 0.028) suggesting a particular role of the collagen in platelet activation. This was shown in the second experiment, in which a significantly increased cumulative volume of PDGF-AB was released from the collagen/glycosaminoglycan scaffold without thrombin activation (p< 0.04). Discussion: This study shows that collagen is a potent activator of platelets, requiring no further additive to achieve satisfactory growth factor release when applied clinically. These results suggest that if PRP is combined with polymer scaffolds, it should be activated with thrombin to achieve optimum growth factor release


Bone & Joint Research
Vol. 8, Issue 2 | Pages 65 - 72
1 Feb 2019
Cowie RM Aiken SS Cooper JJ Jennings LM

Objectives

Bone void fillers are increasingly being used for dead space management in arthroplasty revision surgery. The aim of this study was to investigate the influence of calcium sulphate bone void filler (CS-BVF) on the damage and wear of total knee arthroplasty using experimental wear simulation.

Methods

A total of 18 fixed-bearing U2 total knee arthroplasty system implants (United Orthopedic Corp., Hsinchu, Taiwan) were used. Implants challenged with CS-BVF were compared with new implants (negative controls) and those intentionally scratched with a diamond stylus (positive controls) representative of severe surface damage (n = 6 for each experimental group). Three million cycles (MC) of experimental simulation were carried out to simulate a walking gait cycle. Wear of the ultra-high-molecular-weight polyethylene (UHMWPE) tibial inserts was measured gravimetrically, and damage to articulating surfaces was assessed using profilometry.


Bone & Joint 360
Vol. 2, Issue 3 | Pages 23 - 25
1 Jun 2013

The June 2013 Foot & Ankle Roundup360 looks at: soft-tissue pain following arthroplasty; pigmented villonodular synovitis of the foot and ankle; ankles, allograft and arthritis; open calcaneal fracture; osteochondral lesions in the longer term; severe infections in diabetic feet; absorbable first ray fixation; and showering after foot surgery.